Windlas Biotech Ltd
Q4 FY26
- Revenue
- ₹238.50 Cr
- Profit after tax
- ₹15.99 Cr
As filed with the exchange, consolidated basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q4 FY26 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 238.50 | — | 904.09 |
| Other income | 4.35 | — | 17.80 |
| Total income | 242.85 | — | 921.89 |
| Employee benefit expense | 41.37 | — | 152.09 |
| Finance costs | 1.48 | — | 4.83 |
| Depreciation & amortisation | 8.00 | — | 30.74 |
| Total expenses | 222.69 | — | 834.92 |
| Profit before tax | 20.16 | — | 86.98 |
| Tax expense | 4.17 | — | 20.52 |
| Profit after tax | 15.99 | — | 66.46 |
| Total comprehensive income | 16.07 | — | 66.57 |
| Earnings per share, basic | ₹7.58 | ₹31.60 |
|---|---|---|
| Earnings per share, diluted | ₹7.49 | ₹31.15 |
Q4 FY26 and FY26 — from the company’s filing with NSE. Source
Q4 FY26 results for every company Parakho holds
Why the dash
Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.
Earnings call
Q1 FY27Windlas Biotech reported its highest ever quarterly revenue of Rs 248 crore in Q1 FY27, up 18% year-on-year, marking 14 consecutive quarters of record revenue. The Generic Formulations CDMO vertical grew 29% year-on-year while Trade Generics & Institutional revenue declined following discontinuation of codeine-based products, and Exports grew 79% year-on-year. Management said Plant 6 remains on track for commercialization in H1 FY27 and discussed capacity, working capital and API price volatility during the quarter.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 55 published by the exchange
12 Oct 2026
Filing12 Oct 2026
07 Oct 2026
25 Sept 2026
Insider trading01 Sept 2026
14 Aug 2026
Transcript11 Aug 2026
10 Aug 2026
10 Aug 2026
Presentation10 Aug 2026
Board meeting10 Aug 2026
05 Aug 2026
ConcallAnalyst / Investor Meet - Intimation
Appears 2 times in the recent filings shown; listed once.
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Industry
Healthcare › Pharmaceuticals
Classification as published by BSE.
Companies also in Pharmaceuticals, in alphabetical order
Page generated from filings held to 12 Oct 2026.